CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.43
+6.10%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 121.86x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.89x
- Price / sales
- —
- Price / cash flow
- -19.70x
Enterprise value
- Enterprise value
- $662.9M
- EV / sales
- —
- EV / EBITDA
- -12.87x
- EV / EBIT
- -11.64x
- Market cap
- $877.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026